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1. Introduction  
Cardiovascular disease (CVD) is the predominant cause for morbidity and mortality in 
diabetes mellitus (DM). Patients with diabetes mellitus have two to three times the incidence 
of atherosclerotic disease compared to the general population (Kannel & McGee, 1979). 
Several etiologic factors increase susceptibility to CVD in DM including insulin resistance, 
dyslipidemia, endothelial dysfunction, prothrombosis, and increased protein glycation 
(Baynes & Thorpe, 1999). 
Plasma homocysteine levels are elevated in patients with diabetes, particularly in patients 
with type 2 diabetes as well as in individuals in prediabetic states who exhibit insulin 
resistance. Homocysteine (Hcy) is a non-essential amino acid that is produced from 
demethylation of methionine. Hcy can be remethylated into methionine by means of 
vitamin B12-dependent methionine synthase and 5-methyltetrahydrofolate as a methyl 
donor. Hcy can be also catabolized into cysteine (the transsulfuration pathway) via 
cystathionine beta synthase and cystathioninase, both enzymes being vitamin B6-
dependent. A third way to remove Hcy is conversion to S-adenosylhomocysteine (SAH). 
The last reaction is mediated by SAH-hydrolase and favors the SAH formation in case of 
increased Hcy concentrations. S-Adenosyl methionine (SAM) is a universal methyl donor 
that is formed from methionine and converted into SAH after donating its methyl group. 
SAH is a potent inhibitor of most known methyltransferases (Kloor & Osswald, 2004).  
Among the main determinants of tHcy levels in non-diabetic subjects are age, sex, renal 
function, several diseases, drugs, coffee and chronic alcohol consumption, smoking and 
physical inactivity (Refsum et al., 2006). Genetic factors and nutritional deficiencies of folate 
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or of the vitamin cofactors (vitaminsB12, B6 and B2) involved in Hcy metabolism may also 
promote hyperhomocysteinemia. Besides other genetic defects, a thermolabile variant of 
Methylene Tetrahydrofolate Reductase (MTHFR), a key enzyme of the remethylation 
pathway, has been described (Frosst et al., 1995). It has been shown that this gene variation 
was associated with increased levels of homocysteine; Heterozygotes carrying MTHFR 
thermolabile variant have a reduced enzyme activity (down to 65% of normal levels), while 
homozygotes have only 30% of normal activity (Frosst et al., 1995).  In type 2 diabetic 
patients, levels of homocysteine are influenced by their insulin concentrations, therapy with 
insulin, and medications such as metformin and glitazones that can either raise or lower 
homocysteine levels. 
Epidemiological studies have identified elevated homocysteine (hyperhomocysteinaemia) as 
an independent risk factor for cardiovascular disease. Elevated levels of homocysteine (Hcy) 
above 12.1μmol/L have been shown to double the risk of pathophysiological conditions 
such as atherosclerosis, myocardial infarction, cerebral or peripheral vascular diseases 
(Castro et al., 2006). Mean plasma total Hcy (tHcy) was found to be significantly higher both 
in male and female patients with CAD compared to controls with angiographically normal 
coronary arteries (Kang et al., 1992). An increase in plasma Hcy of only 12% greater than the 
upper limit of normal was shown to be associated with an increase by 3.4- fold in the risk of 
myocardial infarction (Stampfer et al., 1992). After adjusting for possible confounders, 
Arnsen et al. (Arnsen et al., 1995) found a relative risk for coronary heart disease of 1.32 for 
an increase in serum Hcy of 4 μmol/l. A meta-analysis of 27 studies relating Hcy to 
coronary, cerebro vascular and peripheral arterial vascular diseases showed a very strong 
relationship between these diseases and tHcy (Boushey et al., 1995).  
Elevated Hcy may also contribute to progressive atherosclerosis by several mechanisms, 
including arterial endothelial function impairment, oxidative stress induction, and the 
promotion of inflammation and thrombosis (Castro et al., 2006; Wald et al., 2002; 2004; 
Jakubowski, 2006). A unifying hypothesis for the mechanism of Hcy-mediated vascular injury 
has not yet been established. One frequently described mechanism involves oxidative damage, 
as Hcy can undergo autoxidation in the plasma or intracellularly, to form various reactive 
oxygen species (Welch & Loscalzo, 1998). The potent reactive superoxide and hydrogen 
peroxides, which are produced during this process, are mainly responsible for the vascular 
toxicity of homocysteine via the formation of oxidized low density lipoprotein (ox-LDL). The 
oxidation of LDL in the artery wall is believed to be the primary event leading to the initiation 
and progression of atherosclerosis (Steinberg & Witztum, 2002; Parthasarathy et al., 1998). Hcy 
has also been shown to decrease the activity (Nishio & Watanabe, 1997) as well as the 
expression of the antioxidant enzyme glutathione peroxidase (Upchurch et al., 1997). Creation 
of a prothrombotic environment by the action of Hcy on various factors involved in 
coagulation has also been proposed (Ratnoff, 1968; Fryer et al., 1993; Nishinaga et al., 1993). 
The reaction of Hcy with nitric oxide (NO) acts to prevent oxidative damage caused by Hcy 
but at the same time reduces the bioavailability of NO by trapping it intracellularly as a 
nitrosothiol (Jacobsen, 2001). Hcy is also a potent mitogen for vascular smooth-muscle cells 
(Harker et al., 1983; Tsai et al., 1994). Aggregates formed by the combination of Hcy 
thiolactone, a cyclical product of Hcy, with LDL (low-density lipoprotein) were shown to be 
taken up by intimal macrophages and be incorporated into atheromatous plaques 
(Naruszewicz et al., 1994). Hcy thiolactone is also incorporated into cellular and secretory 
proteins through lysine homocysteinylation, leading to the dysfunction of the proteins 
(Jakubowski, 1997). The high density lipoprotein (HDL) particle(s) is known to prevent the 
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formation of ox-LDL by means of the HDL-associated enzyme paraoxonase (PON); its 
antioxidant properties prevent the accumulation of lipid peroxides on LDL (Shih et al., 1998).   
Paraoxonase is a multifunctional antioxidant enzyme that not only can destroy Ox-LDL but 
also can detoxify the homocysteine metabolite, homocysteine thiolactone (Jakubowski H, 
1997). In fact, human paraoxonase possesses a thiolactonase (HTase) activity, hydrolyzing Hcy 
thiolactone to Hcy (Jakubowski, 1999). Hcy thiolactone is likely a natural substrate of 
HTase/paraoxonase (Jakubowski, 2004) a product of the PON1 gene (Furlong et al., 1988). 
The effect of diet on human health has already been underlined in many studies. During the 
past years population-based surveys and large-scale clinical trials have provided scientific 
evidence that diets, and especially those rich in fruits, vegetables, legumes, whole grains, 
fish and low-fat dairy products, are associated with lower incidence of various chronic 
diseases, including diabetes, cardiovascular disease and cancer (Ascherio et al., 1992; appel 
et al., 1997; Price & Fowkes, 1997; koubaa et al., 2007). Diet has also an important role among 
the factors affecting homocysteine levels. Mediterranean diet, with a high proportion of 
bioactive compounds (vitamins, polyphenols and flavonoids) proved its efficiency in 
lowering plasma homocysteine levels and reducing the incidence of cardiovascular disease. 
The aim of the current study was to investigate whether elevated Hcy levels are associated 
with oxidation of LDL, and thiolactonase activity in type 2 diabetic patients, and further 
explore the contribution of various dietary components to prevent diabetes vascular 
complications and atherosclerosis progression. 
2. Patients and methods 
2.1 Study population 
110 diabetic patients (54.2 ± 10.7 years) and 120 non diabetic healthy controls (44 ± 12.3 
years) with available metabolic and life style informations were involved in this study.  
These patients did not receive any antioxidant drugs and none used hormonal replacement 
therapy. The following data were obtained: age, sex, weight. Height hip and waist 
circumference were measured using a standard scale. The study was approved by our 
hospital ethical committee, and informed consent was obtained from all patients before their 
enrolment. Major requirements for enrolment in all the groups were: absence of infectious or 
acute/chronic inflammatory diseases, known malignancy, absence of acute/chronic renal 
failure, or hepatic failure.  
2.2 laboratory procedures 
Validated laboratory procedures were used as described previously (Koubaa et al., 2008). 
Plasmatic total homocysteine (free and protein bound) was determined by a validated 
highly sensitive and accurate capillary gas chromatography mass spectrometry method 
(GC-MS) using a stable isotope as internal standard. Thiolactonase (HTLase) activity was 
estimated by a commercially available kit assay (Alfresa Auto HTLase; Alfresa Pharma 
Corporation, Japan). This method utilizes gamma-thiobutyrolactone as substrate and 
Ellman’s procedure to monitor the accumulation of free sulfhydryl groups via coupling with 
5,5-dithiobis(2-nitrobenzoicacid). Lipids and lipoproteins (Triglycerides: TG; total 
cholesterol: TC mmol/l, High density lipoproteins- cholesterol HDL mmol/l, Low density 
lipoproteins cholesterol: LDL mmol/l, triglycerides: TG mmol/l) concentrations were 
determined by enzymatic way. Apolipoproteins Apo A1 and Apo B were determined by an 
immunoturbidimetric method (Randox, Antrim, UK). Oxidized LDL levels (ox-LDL) were 
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measured by a sandwich ELISA method using a commercial kit (ox-LDL ELISA Kit; 
immunodiagnostic Bensheim,Germany).  The dietary habits of the diabetic patients were 
evaluated. Food intakes were estimated by two dieticians using one-week diet recalls. 
Subjects were asked about their daily diet over a week period: they were asked about 
amounts, frequencies and variations in consumption. Nutrient intakes were calculated using 
the software Nutritionist IV computer analysis (Nutritionist IV Computer Analysis 
Program, 1994, Version 3.1, N2 Computing, Hearst Corp. Salem, OR). 
2.3 Statistical analysis 
Statistical analyses were assessed using the Statistical Package for Social Sciences (SPSS Inc., 
Chicago). Data are presented as median (25th to 75th interquartile range I.R) for several 
variables that were not normally distributed and comparison between the 2 groups was 
performed with the Mann–Whitney U test. The normally distributed values were expressed as 
means with standard deviations and group differences analyzed using the Student's t test. To 
test the association between the variables, either Pearson’s correlations or Spearman’s 
correlation rank (R) were used. Values of p<0.05 were considered to be statistically significant. 
3. Results 
3.1 Participants characteristics 
The clinical and biochemical features of the healthy and diabetic patients are listed in table 1. 
Diabetic patients exhibited significantly higher mean values of systolic and diastolic blood  
 
 Healthy controls (n=120) Diabetics (n=110) p 
Age (years) 44 ± 12.3 54.2 ± 10.7 0.00 
BMI (kg/m2) 26.7 ± 4.0 28.9 ± 5.7 0.00 
WHR 0.91 ± 0.08 0.96 ± 0.07 0.01 
SBP (mm Hg) 12.1 ± 1.2 14.6 ± 9 0.033 
DBP (mm Hg) 7.06 ± 0.9 7.8 ± 1.2 0.00 
Glucose (mmol/L) 5.23 ± 1 10.98 ± 4.2 0.00 
Creatinine (µmol/L) 88.2 ± 19.3 85.8 ± 39.2 0.58 
Urea (mmol/L) 4.9 ± 1.6 6.8 ± 2.7 0.00 
Cholesterol (mmol/L) 4.4 ± 1.2 4.9 ± 1.4 0.00 
Triglycerides (mmol/L) 1.3 ± 0.8 2.1 ± 1.2 0.00 
HDL-C (mmol/L) 1.01 ± 0.28 1.01 ± 0.28 0.97 
LDL-C (mmol/L) 2.7 ± 1.1 3 ± 1.5 0.08 
ApoA1 (g/L) 1.29 ± 0.27 1.39 ± 0.43 0.1 
ApoB (g/L) 0.83 ± 0.28 1.39 ± 0.43 0.03 
tHcy (µmol/L) £ 11.76 (10.7 – 12.81) 12.87 (9.7 – 17.5) 0.01 
ox-LDL (ng/mL) 78.4 ± 23.7 139.6 ± 52.2 0.00 
HTase (U/L) 569.9 ± 254 442.8 ± 211.8 0.01 
SBP, DBP: systolic and diastolic blood pressure  
Values are expressed as mean ± SD 
*: p<0.05; **: p<0.001 
£: expressed as median (I.R) and tested with the Mann Whitney’s U test 
Table 1. Clinical and biochemical features of the healthy Tunisians and diabetic patients 
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pressure (SBP and DBP), Waist to hip Ratio (WHR) and body mass index (BMI). As far as 
the biochemical features of the patients and healthy groups were examined, the diabetics 
exhibited significantly elevated urea levels as compared to healthy subjects (4.9 ± 1.6 vs. 6.8 
± 2.7, p= 0.00). Serum triglycerides and total cholesterol levels were also significantly higher 
in these patients (p = 0.00 and p=0.003 respectively) associated to significantly higher Apo B 
levels. In addition we found a significant increase in plasma homocysteine levels (11.76 (10.7 
– 12.81) vs. 12.87 (9.7 – 17.5) µmol/l; P=0.01) associated with lower Thiolactonase activities 
(442.8 ± 211.8 vs. 569.9 ± 254 U/ml, P=0.01) and higher oxidized LDL levels (139.6 ± 52.2 vs. 
78.4 ± 23.7 ng/ml p = 0.00) as compared to healthy subjects (table 1). 
3.2 Correlations analysis 
The correlations between plasma homocysteine levels, thiolactonase activities and 
oxidized LDL levels were then evaluated with some clinical and biochemical features in 
the diabetic patient’s group. As expected, thiolactonase activities were associated 
negatively with tHcy levels (r= -0.554, p= 0.00), total cholesterol (r= -0.345, p< 0.05), LDL 
levels (r= -0.358, p< 0.05). Oxidized LDL levels were in opposite positively correlated with 
total cholesterol (r= 0.313, p< 0.05), creatinine levels (r= 0.353, p< 0.05) and BMI (r= 0.315, 
p< 0.05).  
 
 tHcy HTase 
ox-
LDL 
BMI TC LDL-C creatinine 
tHcy 1.00 -.554** -.060 .080 .068 .036 .039 
HTase -.554** 1.000 -.198 -.115 -.345* -.358* -.013 
ox-
LDL 
-.060 -.198 1.00 .315 * .313* .260 .353* 
*: p<0.05; **: p<0.001 
£: tested with the Spearman’s test of correlation 
Table 2. Correlations between thiolactonase activity, plasma total homocysteine and 
oxidized LDL levels, with some clinical and biochemical features in the diabetic patients 
3.3 Dietary surveys 
As far as the dietary habits were considered we established that in the diabetic patients, the 
relative percentages of protein intakes per total calories were higher (12.4 ± 1.9 vs. 13.7 ± 3.8 
%, p< 0.05) but the relative percentages of carbohydrate intakes per total calories were lower 
(50.7 ± 7.7 vs. 56.8 ± 5.4 %, p<0.001). The diabetic patient’s diet was significantly richer in 
fats (30.8 ± 5.9 vs. 35.9 ± 7.5 %, p<0.00). They were consuming higher polyunsaturated fatty 
acids (14.2 ± 10.4 vs. 21.6 ± 17.4 %, p<0.00) but significantly lower monounsaturated and 
saturated fatty acids. 
Finally, as the correlations with the nutrients and were examined we noticed that tHcy was 
positively correlated with intakes of protein (r = 0.267, p<0.00), saturated fatty acids (r = 
0.334, p<0.00) and cholesterol (r = 0.265, p<0.05) as illustrated in table 4. Plasma 
homocysteine levels were also correlated with dietary sodium and zinc intakes. 
Thiolactonase activity was negatively associated with proteins (r = -0.345, p<0.05) and 
cholesterol intakes (r = -0.313, p<0.05). Ox LDL levels were positively correlated with lipid 
intakes in the diabetic patients (r = 0.324, p<0.05). 
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 Healthy subjects Diabetics 
Proteins (%) 12.4 ± 1.9 13.7 ± 3.8* 
A/V 1.06 ± 0.27 1.1 ± 0.48 
Carbohydrates 
(%) 
56.8 ± 5.4 50.7 ± 7.7** 
Fats (%) 30.8 ± 5.9 35.9 ± 7.5 ** 
SFA 23.2 ± 9.4 16.8 ± 8.1** 
MUFA 46.9 ± 9.4 32.9 ± 14.8** 
PUFA 14.2 ± 10.4 21.6 ± 17.4* 
Cholesterol (mg) 188.2 ± 154 507.4 ± 206 
Calcium(mg) 483.1 ± 154.3 507.4 ± 206 
Vitamin B1 (mg) 0.49 ± 0.12 0.48 ± 0.16 
Fiber (g) 16.3 ± 4.7 34.2 ± 15.5 
Vitamin C (mg) 77.5± 30.4 82.7 ± 50.5 
Vitamin E (mg) 7.1 ± 3.4 9.9 ± 10 
Folates (µg) 134.4 ± 54.9 157.4 ±  71.2 
A/V: percentage of Animal protein/ percentage of vegetal protein; 
SFA: Saturated fatty acids, 
MUFA: Monounsaturated fatty acids,  
PUFA: Polyunsaturated fatty acids and. 
*: p<0.05; **: p<0.001 
Table 3. Daily nutrient intakes of the healthy and diabetic patients 
 
 
Proteins 
(%) 
Fats 
(%) 
SFA 
Cholester
ol 
Sodium Zinc 
tHcy £ .267** -.138 .334** .265* .324* .272* 
HTase -.345* .226 -.012 -.313* -.261 .211 
ox-
LDL 
-.091 .324* -.028 -.038 -.234 -.260 
*: p<0.05; **: p<0.001 
£: tested with the Spearman’s test of correlation 
Table 4. Correlations between thiolactonase activity, plasma total homocysteine and 
oxidized LDL levels with selected nutrients in the diabetic patients 
4. Discussion 
Diabetic subjects constitute a patient population at high risk for cardiovascular disease, 
due to the influence of a clustering of risk factors. Plasma tHcy is considered as an 
emerging independent nontraditional risk factor for atherosclerotic vascular disease, 
which may enhance the effect of the traditional risk factors (Graham, 1997; Hackam & 
Anand, 2003). It is also a strong predictor of cardiovascular and all-cause mortality 
(Bostom et al., 1999). Therefore, it is important to know if dietary habits and lifestyle can 
affect plasma tHcy levels in this population, and eventually select the patients who would 
be at a higher risk for developing such complications. In the present study, tHcy levels 
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were higher in the diabetic patient’s group. Plasma tHcy levels have been studied 
extensively in diabetic, as well as in non-diabetic subjects. A number of studies did not 
find any differences in plasma tHcy values between diabetic and control subjects (Salarde 
et al., 2000; Lanfredini et al., 1998; Pavia et al. 2000, Diakoumopoulou et al., 2005). Some 
investigators demonstrated lower levels of tHcy in diabetics versus controls (Matteucci et 
al., 2002; Wollesen et al., 1999; Salardi et al., 2000). However, our findings are in 
accordance with other reports where tHcy were higher in the diabetic patients (Passaro et 
al., 2000; Yeromenko et al., 2000). Furthermore, homocysteine increases the production of 
ox-LDL and enhances their uptake by macrophages leading to the formation of foam cells 
that play a crucial role in atherosclerotic lesions (Tsai et al.,). Ox-LDL are considered as 
biochemical markers of coronary artery disease (Toshima et al., 2000 ; Holvoet et al, 2001). 
Accordingly, we found high levels of ox-LDL in diabetic patients exhibiting the highest 
levels of tHcy, which confirms the oxidative effect of homocysteine in the type 2 DM 
patients. Every 5 μM/L increase in the Hcy concentration increases the risk of CVD by 
50%, and TC levels by 20 mg/dL. (Castro et al., 2006; Wald et al., 2002; Nygard et al., 1998; 
Genset et al., 1990). The mechanisms possibly responsible for causing endothelial 
dysfunction include changes in LDL, and Ox- LDL. The oxidation of LDL is increased by 
the combination of thiolactone and apo B’s free lysyl epsilon amino residue (Rocchi et al., 
2007; Mansoor et al., 1993, 2000). When LDL is reacted with Hcythiolactone in methionine, 
which is an explicit initiator of arteriosclerosis, LDL-binding thiol is increased by 250 nM 
per mg of LDL protein (Ferguson et al. 1999). The free amino- or thiol-adducted LDL 
causes aggregation, and increases LDL uptake in macrophages and atheroma production 
by lipids (Perna et al., 2003). Another mechanism by which Hcy may cause LDL oxidation 
is a possible deformation of LDL through Hcy autoxidation, which causes the oxidation of 
side chains of LDL such as fatty acids or apo B- 100 (Young & Woodside , 2000). Both Hcy 
and Ox-LDL could participate in thrombosis by increasing VCAM-1 and ICAM-1, caused 
by endothelial cell activation due to fibrinogen-platelet GPIIb-lIIa formation. Ox-LDL 
affects both initial and progressive stages of arteriosclerosis (Jakubowski, 2000; Dardik et 
al., 2000; Vadachkoria et al., 2004; Erl et al., 2000). On the other hand, circulating Hcy 
reduces NO-induced detoxification, vasodilation, and endothelial function (Rocchi et al., 
2007). NO participates in a metabolic pathway (S-nitroso-HCY) that is able to protect 
against Hcy-induced endothelial oxidative damage. Paraoxonase plays also a key role in 
reducing Hcy endothelial damages. In our previous results, we found a decline in 
endogenous antioxidant defense system capability in type 2 DM patients indicating their 
high oxidative stress (Smaoui et al., 2006). Antioxidant status of enzymes in DM patients 
is controversial. Several authors have reported that lipid peroxides level increases in type 
2 DM patients (Mooradian, 1991); on the other hand, other studies found no significant 
increase in these patients (Velazquez et al., 1991). Among the numerous antioxidant 
enzymes, we focused in the present study on the thiolactonase activities which were 
decreased in the diabetic patients. Most studies evaluated the paraoxonase activity in 
Type I and Type II diabetic patients and found a decreased activity in these patients 
(Boemi et al., 2001; Kordonouri et al., 2001; Letellier et al., 2002; Mackness B et al., 1998; 
2002; Agachan et al., 2004). Paraoxonase is a multifunctional antioxidant enzyme that not 
only can detoxify paraoxon, destroy oxidized low-density lipoprotein (ox-LDL) but also 
can hydrolyze homocysteine thiolactone. 
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The mechanism by which PON1 is reduced in diabetes is poorly understood, but may be 
associated with an increase in blood glucose concentration. Glycation can both inactivate 
PON1 and increase lipid peroxidation in HDL (Hedrick et al., 2000). Glycated HDL also has 
a reduced ability to protect against oxidation (Ferretti et al., 2001). PON1 activity and 
concentration were decreased also in studies of healthy subjects with elevated fasting 
glucose levels (Leviev et al., 2001; Kordonouri et al., 2001). Our finding showed a negative 
association between HTase activities, tHcy levels and oxidized LDL levels. These levels were 
associated with higher triglycerides, total cholesterol and also higher Apo B levels.  Apo B is 
superior to cholesterol and triglycerides as a coronary syndrome risk factor due to the 
heterogeneity of lipoprotein particle composition. In fact, plasma Apo B concentrations 
reflect the number of atherogenic lipoprotein particles including LDL, and chylomicron 
remnants which contain variable amounts of triglycerides and cholesterol, but each of these 
particles contain 1 molecule of Apo B as structural protein. Then, higher levels of Apo B 
found in the diabetic patients reflects their higher risk for developing cardiovascular 
diseases (Sniderman et al., 1997).  
The SBP and DBP were also increased in the diabetic patients. The association between 
homocysteine and chronic complications of diabetes mellitus could be explained by 
different mechanisms; direct toxic effect on vascular endothelial and indirect effect on the 
normal methylation in endothelial cells (Weir & Molloy, 2000). Direct toxic effect of 
homocysteine could be mediated by damage to vascular endothelial cells, resulting in 
vascular events, such as microvascular disease. In the study of Fiorina et al. (Fiorina et al., 
1998), Caucasian patients with elevated tHcy levels had significantly higher diastolic 
pressure and mean arterial pressure. These results are similar to our data. Other populations 
(Indians) have shown correlation between homocysteine concentrations and body weight 
(Das et al., 1999). Our results did not show correlations among tHcy and different 
anthropometric parameters (body mass index, waist to hip ratio). Nevertheless, a positive 
correlation between ox-LDL levels and BMI was established in the diabetic patients. There 
was also a positive association between ox-LDL levels and creatinine levels in the diabetic 
patients. No correlation was found between creatinine and tHcy levels. Most studies have 
been able to show a positive correlation between plasma Hcy and plasma creatinine levels, 
suggesting the importance of the kidney in the regulation of plasma Hcy. Renal function in 
Type 2 diabetes appears to change with the progress of the disease: hyperfiltration in the 
early stages and progressive deterioration with the progression of diabetes. Diabetes 
therefore provides an interesting situation with changes in kidney functions being 
superimposed on the already existing changes in the metabolic milieu. Moreover, we found 
a negative association between HTase activities tHcy levels and the levels of total cholesterol 
and ox-LDL. In fact, in certain diseases e.g. diabetes where HDL size is reduced, secretion of 
PON1 is affected due to the fact that PON1 tends to bind to larger sized species of HDL both 
in vivo (Blatter et al.,1993) and  in vitro (Deakin et al., 2002). In addition, in vitro studies 
demonstrated that PON1 was inactivated by oxidized lipids and oxidized LDL (Aviram et 
al., 1999).  PON1 is highly susceptible to inactivation by oxidation. In vitro, PON1 activity is 
protected by the antioxidant polyphenols quercetin and glabridin (Aviram et al., 1999), 
suggesting that dietary antioxidants may play a similar role in vivo. Studies have shown 
that consumption of pomegranate juice, rich in polyphenols and other antioxidants, can 
raise PON1 activity up to 20% in both humans and apoE knockout mice (Kaplan et al., 2001). 
Polyphenols extracted from red wine also increase PON1 activity in mice (Hayek et al., 
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1997). Recent work from Gou´edard et al. (Gou´edard et al., 2004) provides evidence that 
dietary polyphenols can influence PON1 gene expression. Clinical trials of the antioxidant 
vitamins C and E have, to date, been unsuccessful in showing a link between vitamin intake 
and CHD risk. Likewise, their effect, if any, on PON1 activity is not clear. Jarvik et al. (Jarvik 
et al., 2002) found that PON1 activity correlated positively with the quantity of vitamins C 
and E in the diet; however, another study in which vitamin E was given to volunteers 
showed no change in PON1 activity (Arrol et al., 2000). In contrast, oleic acid from olive oil 
is associated with increased activity (Tomas et al., 2001; Wallace et al., 2001). Meals rich in 
used cooking fat, which contains a high content of oxidized lipids, were followed by a 
significant fall in PON1 activity when fed to healthy men (Sutherland et al., 1999). These 
correlations were not confirmed by our results. The thiolactonase activities were correlated 
negatively with protein and cholesterol intakes. Plasma homocysteine levels were in 
opposite positively correlated to protein intakes, the relative percentage of fats and 
saturated fatty acids in diet and sodium intakes. Accordingly, in the Hordaland study that 
included 5917 subjects, a higher intake of saturated fatty acids was positively associated 
with higher concentrations of plasma Hcy. Concentrations of Hcy were higher (by 8.8%) in 
the group with the highest intakes of saturated fatty acids compared to that with the lowest 
intake (Berstad et al., 2007). Food-based feeding trials have shown a reduction in blood Hcy 
in subjects who consume fortified cereals or whole grains in combination with fruits, 
vegetables and low fat dairy products (Lutsey et al., 2006; Appel et al., 2000). Several 
carefully studied populations in Mediterranean countries and in some areas in Asia, where 
traditional diets consist largely of foods of plant origin, exhibit low rates of many chronic 
diseases and long life expectancies. Many case-control and prospective studies have 
provided further evidence that high consumption of plant foods confers numerous health 
benefits. Although the mechanisms are not fully understood, carotenoids, folic acid, and 
fiber, all of which are abundant in the Mediterranean diet, appear to play important roles in 
the prevention of coronary artery disease (Kushi et al., 1995).  
5. Conclusion 
In conclusion, Hcy and thiolactonase activities and oxidized levels are interrelated in type 2 
diabetic patients and are responsible, at least partly, of the vascular complications. Strong 
evidence suggested that excess of plasma homocysteine disturb lipid metabolism via the 
oxidation of LDL particle and its aggregation, and enhancing atherosclerosis progression. 
Another line of evidence suggested that thiolactonase activity is affect in diabetics partly by 
a glycation process that accentuates the endothelial damages of homocysteine. A very 
interesting aspect to be tested in future studies is the beneficial effect of certain nutriments 
on lipid parameters and plasma homocysteine levels. Future long-term studies on larger 
populations are needed for determining the exact role of homocysteine in the development 
of diabetes vascular complications and the metabolic ways of prevention. 
6. Acknowledgment  
This work was supported by a grant from the “Ministère de l'Enseignement Supérieur, de la 
Recherche Scientifique et de la Technologie” UR “Nutrition Humaine et Désordres 
Métaboliques” UR03ES08 and USCR-Spectrométrie de masse. We would like to thank 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
188 
Alfresa Pharma Corporation, Japan for their assistance. We are also thankful to all the 
clinicians for their assistance with patients and controls recruitment. 
7. References  
Agachan, B., Yilmaz, H., Karaali, Z. and Isbir, T. (2004). Paraoxonase 55 and 192 
polymorphism and its relationship to serum paraoxonase activity and serum lipids 
in Turkish patients with non-insulin dependent diabetes mellitus. Cell. Biochem. 
Funct. Vol.22, pp.163–168.  
Appel, L., Moore, T., Obarzanek, E., Vollmer, W., Svetkey, L., Sacks, F.,  Bray, G.A., Vogt, 
T.M., Cutler, J.A., Windhauser, M,M., Lin, P.H., Karanja, N.A. (1997). Clinical trial 
of the effects of dietary patterns on blood pressure.  N Engl J Med.   Vol.336, 
pp.1117-24. 
Appel, L.J., Miller, E.R., Jee, S.H., Stolzenberg-Solomon, R., Lin, P.H., Erlinger, T. (2000). 
Effect of dietary patterns on serum homocysteine: results of a randomized, 
controlled feeding study. Circulation. Vol.102, pp. 852-7. 
Arnesen, E., Refsum, H., Bonaa, K.H., Ueland, P.M., Forde, O.H., Nordrehaug, J.E.  (1995). 
Serum total homocysteine and coronary heart disease.  Int. J. Epidemiol, vol.24, 
pp.704–709. 
Arrol, S., Mackness, M. I. and Durrington, P. N. (2000). Vitamin E supplementaion increases 
the resistance of both LDL and HDL to oxidation and increases cholesteryl ester 
transfer activity. Atherosclerosis. Vol.150, pp.129–134. 
Ascherio, A., Rimm, E.B., Giovannucci, E.L. (1992). A prospective study of nutritional factors 
and hypertension among US men. Circulation, vol.86, pp. 475-84. 
Aviram, M., Rosenblat, M., Billecke, S. (1999). Human serum paraoxonase (PON1) is 
inactivated by oxidised low density lipoprotein and preserved by antioxidants. Free 
Radicals Biol. Med. Vol.26, pp.892–904. 
Baynes JW, Thorpe SR. (1999). Role of oxidative stress in diabetic complications: a new 
perspective on an old paradigm. Diabetes, vol.48, pp.1-9. 
Berstad, P., Konstantinova, S.V., Refsum, H., Nurk, E., Vollset, S.E, Tell, G.S., Ueland, P.M, 
Drevon, C.A, Ursin, G. (2007).Dietary fat 
 andplasma total homocysteine concentrations in 2 adult age groups: the 
hordaland Homocysteine Study. Am. J. Clin. Nutr. Vol.85, pp.1598–1605. 
Blatter, M.C., James, R. W., Messmer, S., Barja, F. and Pometta, D. (1993). Identification of a 
distinct human high-density lipoprotein subspecies defined by a lipoprotein-
associated protein, K-45. Identity of K-45 with  paraoxonase. Eur. J. Biochem. Vol. 
211, pp. 871–879 
Boemi, M., Leviev, I., Sirolla, C., Pieri, C., Marra, M. and James, R. W. (2001). Serum 
paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first 
degree relatives; influence on the ability of HDL to protect LDL from oxidation. 
Atherosclerosis. Vol.155, pp.229–35. 
Bostom, A.G., Silberhatz, H., Rosenberg, I.H., Selhub, J., D’Agostino, R.B., Wolf, P.A. (1999). 
Non-fasting plasma total homocysteine levels and all-cause and cardiovascular 
disease mortality in elderly Framingham men and women. Arch Intern Med. 
Vol.159, pp.1077-80. 
www.intechopen.com
Interactions Between Total Plasma Homocysteine, Oxidized  
LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients 
 
189 
Boushey, C.J., Beresford, S.A., Omenn, G.S. and Motulsky, A.G. (1995). A quantitative 
assessment of plasma homocysteine as a risk factor for vascular disease. Probable 
benefits of increasing folic acid intakes. J. Am. Med. Assoc. vol.274, pp. 1049–1057. 
Castro, R., Rivera I, Blom, H.J., Jakobs, C., Tavares de Almeida, I. (2006). Homocysteine 
metabolism, hyperhomocystenemia and vascular disease: an overview. J Inherit 
Metab Dis, vol.29, pp.3-20. 
Castro, R., Rivera, I., Blom, H.J., Jakobs, C., Tavares de Almeida, I. (2006). Homocysteine 
metabolism, hyperhomocystenemia and vascular disease: an overview. J Inherit 
Metab Dis. Vol.29, pp.3-20. 
Dardik, R., Varon, D., Tamarin, I., Zivelin, A., Salomon, O., Shenkman, B. (2000). 
Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to 
endothelial cells under flow conditions: distinct mechanisms of thrombogenic 
modulation. Thromb Haemost. Vol.83, pp.338-44. 
Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G. and James, R. W. 
(2002). Enzymatically active paraoxonase-1 is located at the external membrane of 
producing cells and released by a high affinity, saturable, desorption mechanism. J. 
Biol. Chem. Vol.277,  pp.4301–4308. 
Diakoumopoulou, E., Tentolouris, N., Kirlaki, E., Perrea, D., Kitsou, E., Psallas, 
M., Doulgerakis, D., Katsilambros N. (2005). Plasma homocysteine levels in patients 
with type 2 diabetes in a Mediterranean population: relation with nutritional and 
other factors. Nutr Metab Cardiovasc Dis.  Vol.15, n.(2), pp.109-17 
Erl, W., Weber, P.C., Weber, C. (1998). Monocytic cell adhesion to endothelial cells 
stimulated by oxidized low density lipoprotein is mediated by distinct endothelial 
ligands. Atherosclerosis. Vol.136, pp.297-303. 
Ferguson, E., Hogg, N., Antholine, W.E., Joseph, J., Singh, R.J., Parthasarathy, S. (1999). 
Characterization of the adduct formed from the reaction between homocysteine 
thiolactone and low-density lipoprotein: antioxidant implications. Free Radic Biol 
Med. Vol.26, pp. 968-77. 
Ferretti, G., Bacchetti, T., Marchionni, C., Caldarelli, L. and Curatola, G. (2001). Effect of 
glycation of high density lipoproteins on their physiochemical properties and on 
paraoxonase activity. Acta Diabetol. Vol.38, pp.163–169. 
Frosst, P., Blom, H.J., Milos, R., Goyette, P., Sheppard, C.A., Metthews, R.G. (1995). A 
candidate genetic risk factor for vascular disease: a common mutation in 
methylenetetrahydrofolate reductase. Nat Genet. Vol.10, pp.111–3. 
Fryer, R.H., Wilson, B.D., Gubler, D.B., Fitzgerald, L.A., Rodgers, G.M. (1993). 
Homocysteine, a risk factor for premature vascular disease and thrombosis, 
induces tissue factor activity in endothelial cells Arterioscler. Thromb. Vol.13, 
pp.1327–1333. 
Furlong, C.E., Richter, R.J., Seidel, S.L., Motulsky, A.G. (1988). Role of genetic polymorphism 
of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide 
metabolites chlorpyrifos oxon and paraoxon. Am J Hum Genet. Vol.43, pp.230–8. 
Genest, J.J. Jr, McNamara ,J.R., Salem, D.N., Wilson, P.W., Schaefer, E.J., Malinow, M.R. 
(1990).Plasma homocyst(e)ine levels in men with premature coronary artery 
disease. J Am Coll Cardiol. Vol.16, pp.1114-9. 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
190 
Gouedard, C., Barouki, R. and Morel, Y. (2004). Dietary polyphenols increase paraoxonase 1 
gene expression by an aryl hydrocarbon receptor-dependant mechanism. Mol. Cell. 
Biol. Vol.24, pp.5209–5222. 
Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, L.E., Ueland, P.M. (1997). 
Plasma homocysteine as a risk factor for vascular disease. The European Concerted 
Action Project. J Am Med Assoc. vol.277, n.(22), pp. 1775-81. 
Hackam, D.G., Anand, S.S. (2003). Emerging risk factors for atherosclerotic vascular disease. 
J Am Med Assoc. vol.290, pp.932-40. 
Harker, L.A., Harlan, J.M., Ross, R. (1983). Effect of sulfinpyrazone on homocysteine-
induced endothelial injury and arteriosclerosis in baboons.  Circ. Res. Vol.53, 
pp.731–739.  
Hayek, T., Fuhrman, B., Vaya, J. et al. (1997). Reduced progression of atherosclerosis in the 
apolipoprotein E deficient mice following consumption of red wine, or its 
polyphenols quercetin, or catechin, is associated with reduced susceptibility of LDL 
to oxidation and to aggregation. Arterioscler., Thromb., Vasc. Biol. Vol.17, pp.2744–
2752. 
Hedrick, C. C., Thorpe, S. R., Fu, M. X. et al. (2000). Glycation impairs high-density 
lipoprotein function.  Diabetologia. Vol.43, pp.312–320. 
Holvoe,t P., Mertens, A., Verhamme, P. (2001). Circulating oxidized LDL is a useful marker 
for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol.  
Vol.21, pp.844–8. 
Jacobsen, D.W. (2001) in Homocysteine in Health and Disease (Carmel, R. and Jacobsen, 
D.W., eds), pp. 425–440, Cambridge University Press, Cambridge 
Jakubowski, H. (1997). Metabolism of homocysteine thiolactone in human cell cultures. J Biol 
Chem. vol. 272, pp.1935-42. 
Jakubowski, H. (2000). Homocysteine thiolactone: metabolic origin and protein 
homocysteinylation in humans. J Nutr. Vol.130, pp.377-81. 
Jakubowski, H. (2004). Biochemical basis of homocysteine toxicity in humans. Mol Cell Life 
Sci. vol.61, pp.470–87. Jakubowski,  H. (1999).Protein homocysteinylation: possible 
mechanism underlying pathological consequences of elevated homocysteine levels. 
FASEB J. vol.13, pp.2277–83. 
Jakubowski, H. (2006). Pathophysiological consequences of homocysteine excess. J Nutr. 
Vol.136, pp.1741-9. 
Jarvik, G. P., Tsai, N. T., McKinstry, L. A. (2002). Vitamin C and E intake is associated with 
increased paraoxonase activity. Arterioscler., Thromb., Vasc. Biol. Vol.22, pp.1329–
1333 
Kang, S.S., Wong, P.W., Malinow, M.R. (1992). Hyperhomocyst(e)inemia as a risk factor for 
occlusive vascular disease. Annu. Rev. Nutr. vol.12, pp.279–298. 
Kannel, WB., McGee, DL. (1979). Diabetes and cardiovascular disease. The Framingham 
study. JAMA, vol.241, pp.2035–2038. 
Kaplan, M., Hayek, T., Raz, A. et al. (2001). Pomegranate juice supplementation to 
atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol 
accumulation and development of atherosclerosis.J. Nutr. Vol.131, pp.2082–2089. 
Kloor, D., Osswald, H. (2004) S-Adenosylhomocysteine hydrolase as a target for 
intracellular adenosine action. Trends Pharmacol. Sci. vol.25, pp. 294–297. 
www.intechopen.com
Interactions Between Total Plasma Homocysteine, Oxidized  
LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients 
 
191 
Kordonouri, O., James, R. W., Bennetts, B. (2001). Modulation by blood glucose levels of 
activity and concentration of paraoxonase in young patients with type 1 diabetes 
mellitus. Metab. Clin. Exp. Vol.50, pp. 657–660. 
Koubaa, N., Hammami, S., Nakbi, A., Ben Hamda, K., Mahjoub, S., Kosaka, T.  Hammami, 
M. (2008). Relationship between thiolactonase activity and hyperhomocysteinemia 
according to MTHFR gene polymorphism in Tunisian Behcet’s disease patients. 
Clin Chem Lab Med. Vol. 46, n.(2), pp.187–192.  
Koubaa, N., Nakbi, A., Smaoui, M., Abid, N., Chaaba, R., Abid, M., Hammami, M.  (200 7). 
Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: 
Role of genetic and dietary factors. Clin Biochem. Vol.40, pp.1007–1014. 
Kushi, L.H., Lenart, E.B., Willett, W.C. (1995). Health implications of Mediterranean diets in 
light of contemporary knowledge. 1. Plant foods and dairy products. Am J Clin 
Nutr. Vol.61(suppl), pp.1407–15. 
Lanfredini, M., Fiorina, P., Peca, M.G., Veronelli, A., Mello, A., Astorri, E., Dall'Aglio, P., 
Craveri, A. (1998). Fasting and post-methionine load homocyst(e)ine values are 
correlated with microalbuminuria and could contribute to worsening vascular 
damage in non-insulin-dependent diabetes mellitus patients. Metabolism. Vol.47, 
pp.915-21. 
Letellier, C., Durou, M. R., Jouanolle, A. M., Le Gall, J. Y., Poirier, J. Y. and Ruelland, A. 
(2002). Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 
diabetic patients with or without vascular complications. Diabetes Metab. Vol.28, pp. 
297–304. 
Leviev, I., Kalix, B., Brulhart Meynet, M.-C. and James, R. W. (2001). The paraoxonase PON1 
promoter polymorphism C(−107)T is associated with increased serum glucose 
concentrations in non-diabetic patients. Diabetologia. Vol. 44, pp.1177–1183. 
Lutsey, P.L., Steffen, L.M., Feldman, H.A., Hoelscher, D.H., Webber, L.S., Luepker, R.V. 
(2006). Serum homocysteine is related to food intake in adolescents: the Child and 
Adolescent Trial for Cardiovascular Health. Am J Clin Nutr. Vol.83, pp.1380-6. 
Mackness, B., Durrington, P. N., Boulton, A. J., Hine, D. and Mackness, M. I. (2002). Serum 
paraoxonase activity in patients with type 1 diabetes compared to healthy controls. 
Eur. J. Clin. Invest. Vol.32, pp. 259–256. 
Mackness, B., Mackness, M. I., Arrol, S. et al. (1998) Serum paraoxonase (PON1) 55 and 192 
polymorphism and paraoxonase activity and concentration in non-insulin 
dependent diabetes mellitus. Atherosclerosis. Vol.139, pp. 341–349.  
Majors, A., Ehrhart, L.A., Pezacka, E.H. (1997). Homocysteine as a risk factor for vascular 
disease, enhanced collagen production and accumulation by smooth muscle cells. 
Arterioscler Thromb Vasc Biol. Vol.17, pp.2074–81.  
Mansoor, M.A., Bergmark, C., Haswell, S.J., Savage, I.F., Evans, P.H., Berge, R.K. (2000). 
Correlation between plasma total homocysteine and copper in patients with 
peripheral vascular disease. Clin Chem. Vol.46, pp.385-91. 
Mansoor, M.A., Ueland, P.M., Aarsland, A., Svardal, A.M. (1993). Redox status and protein 
binding of plasma  homocysteine and other aminothiols in patients with 
homocystinuria. Metabolism. Vol. 42, pp.1481-5. 
Matteucci, E., Rossi, L., Mariani, S., Fagnani, F., Quilici, V., Cinapri, V. (2002). Blood levels of 
total homocysteine in patients with type 1 diabetes (with no complications, diabetic 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
192 
nephropathy and/or retinopathy) and in their non-diabetic relatives. Nutr Metab 
Cardiovasc Dis. Vol.12, pp. 184-9. 
Mooradian, A.D. (1991). Increased serum conjugated dienes in elderly diabetic patients. J 
Am Geriatr Soc. Vol. 39, pp.571–5. 
Naruszewicz, M., Mirkiewicz, E., Olszewski, A.J. and McCully, K.S. (1994). Nutr. Metab. 
Cardiovasc. Dis. Vol.4,  pp.70–77. 
Nishinaga, M., Ozawa, T. and Shimada, K. (1993). Homocysteine, a thrombogenic agent, 
suppresses anticoagulant heparan sulfate expression in cultured porcine aortic 
endothelial cells.  J. Clin. Invest. vol.92, pp.1381–1386. 
Nishio, E., Watanabe Y. Br. (1997). Oxidized LDL induces apoptosis in cultured smooth 
muscle cells: a possible role for 7-ketocholesterol. J. Pharmacol. Vol.122, pp.269–274. 
Nygård, O., Refsum, H., Ueland, P.M., Vollset, S.E. (1998). Major lifestyle determinants of 
plasma total homocysteine distribution: the Hordaland Homocysteine Study. Am J 
Clin Nutr. Vol.67, pp.263-70. 
Parthasarathy. S., Santanam, N., Auge, N.  (1998). Oxidised low-density lipoprotein: a two-
faced Janus in coronary artery disease? Biochem pharmacol. Vol.56, pp.279–284. 
Passaro, A., D’Ellia, K., Pareschi, P.L., Calzoni, F., Carantoni, M., Fellin, R. (2000). Factors 
influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care. Vol.23, 
pp.420-1. 
Pavia ,C., Ferrer, I., Valls, C., Artuch, R., Colome, C., Vilaseca, M.A. (2000). Total 
homocysteine in patients with type 1 diabetes. Diabetes Care. Vol.23, pp.84-7. 
Perna, A.F., Ingrosso, D., Lombardi, C., Acanfora, F., Satta, E., Cesare, C.M. (2003). Possible 
mechanisms of homocysteine toxicity. Kidney Int Suppl. Vol.84, pp.137-40. 
Price, J.F., Fowkes, F.G.R. (1997). Antioxidant vitamins in the prevention of cardiovascular 
disease.  Eur Heart J. vol.18, pp.719-27.  
Ratnoff, O.D. (1968). Activation of Hageman factor by L-homocystine.  Science. Vol.162, 
pp.1007–1009. 
Refsum, H., Nurk, E., Smith, A.D., Ueland, P.M., Gjesdal, C,G., Bjelland, I., Tverdal, A., Tell, 
G.S., Nygard, O., Vollset, S.E. (2006).The Hordaland Homocysteine Study: a 
community-based study of homocysteine, its determinants, and associations with 
disease. J Nutr. Vol.136, pp. 1731–1740.  
Rocchi, E., Bursi, F., Ventura, P., Ronzoni, A., Gozzi, C., Casalgrandi,  G. (2007). Anti- and 
pro-oxidant factors and endothelial dysfunction in chronic cigarette smokers with 
coronary heart disease. Eur J Intern Med. Vol.18, pp.314-20. 
Salardi, S., Cacciari, E., Sassi, S., Grossi, G., Mainetti, B., Dalla Casa, C. (2000). 
Homocysteinemia, serum folate and vitaminB12 in very young patients with 
diabetes mellitus type 1. J Pediatr Endocrinol Metab. Vol.13, pp.1621-7. 
Shih, D.M., Gu, L., Xia, Y.R., Navab, M., Li, W.F., Hama, S. (1998). Mice lacking serum 
paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. 
Nature. Vol.394, pp.284-7. 
Smaoui, M., Koubaa, N., Hammami, S., Abid, N., Feki, M., Chaaba, R., Attia, N., Abid, M., 
Hammami, M. (2006). Association between dietary fat and antioxidant status of 
Tunisian type 2 diabetic patients. Prostaglandins,Leukot Essent Fat Acids. Vol.74, 
pp.323–9. 
www.intechopen.com
Interactions Between Total Plasma Homocysteine, Oxidized  
LDL Levels, Thiolactonase Activities and Dietary Habits in Tunisian Diabetic Patients 
 
193 
Sniderman, A.D., Pedersen, T., Kjekshus, J. (1997).  Putting low-density lipoproteins at 
center stage in atherogenesis. Am J Cardiol. Vol.79, n.(1), pp.64-67. 
Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., Upson, B., Ullmann, D., 
Tishler, P.V, Hennekens, C.H. (1992). A prospective study of plasma 
homocyst(e)ine and risk of myocardial infarction in US physicians. J. Am.Med. 
Assoc. vol. 268 pp. 877–881. 
Steinberg, D., Witztum, J.L.  (2002). Is the oxidative modifications hypothesis relevant to 
human atherosclerosis? Do the antioxidant trials conducted to date reflect the 
hypothesis?. Circulation. Vol.105, pp.2107–2111. 
Sutherland, W. H., Walker, R. J., de Jong, S. A., van Rij, A. M., Phillips, V. and Walker, H. L. 
(1999). Reduced postprandial serum paraoxonase activity after a meal rich in used 
cooking fat. Arterioscler., Thromb., Vasc. Biol. Vol.19, pp.1340–1347. 
Tomas, M., Senti, M., Eluosa, R. (2001). Interaction between the Gln-Arg 192 variants of the 
paraoxonase gene and oleic acid intake as a determinant of high density lipoprotein 
cholesterol and paraoxonase activity. Eur. J. Pharmacol. Vol.432,  pp.121–128. 
Toshima, S., Hasegawa, A., Kurabayashi, M. (2000). Circulating oxidized low density 
lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscler 
Thromb Vasc Biol. Vol.20, pp.2243–7. 
Tsai, J.C., Perrella, M.A., Yoshizumi, M., Hsieh, C.M., Haber, E., Schlegel, R., Lee, M.E. 
(1994). Promotion of vascular smooth muscle cell growth by homocysteine: a link to 
atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. vol.91, pp.6369–6373. 
Tsai, M., Garg, U., Key, N.S. (1996). Molecular and biochemical approaches in the 
identification of heterozygotes for homocystinuria. Atherosclerosis. Vol.172, pp.69–
77. 
Upchurch, Jr, G.R., Welch, G.N., Fabian, A.J., Freedman, J.E., Johnson, J.L., Keaney, Jr, J.F. 
and Loscalzo, J. (1997). Homocyst(e)ine decreases bioavailable nitric oxide by a 
mechanism involving glutathione peroxidase. J. Biol. Chem. Vol.272, pp.17012–
17017. 
Vadachkoria, S., Sanchez, S.E., Qiu, C., Muy-Rivera, M., Malinow, M.R., Williams, M.A. 
(2004). Hyperhomocyst(e)inemia and elevated soluble vascular cell adhesion 
molecule-1 concentrations are associated with an increased risk of preeclampsia. 
Gynecol Obstet Invest. Vol.58, pp.133-9. 
Velazquez, E., Winocour, P.H., Kesteven, P., Alberti, K.G., Laker, M.F. (1991). Relation of 
lipid peroxides to macrovascular disease in type 2 diabetes. Diabet Med.  Vol.88, 
pp.752–8. 
Wald D.S., Law M, Morris JK. (2004). The dose-response relation between serum 
homocysteine and cardiovascular disease: implications for treatment and screening. 
Eur J Cardiovasc Prev Rehabil. Vol.11, pp.250-3. 
Wald D.S., Law, M., Morris, J.K. (2002). Homocysteine and cardiovascular disease: evidence 
on causality from a meta-analysis. BMJ. Vol.325, pp.1202. 
Wald, D.S., Law, M., Morris, J.K. (2002). Homocysteine and cardiovascular disease: evidence 
on causality from a meta-analysis. BMJ. Vol. 325, pp.1202. 
Wallace, A. J., Sutherland, W. H., Mann, J. I. and Williams, S. M. (2001). The effect of meals 
rich in thermally stressed olive and safflower oils on postprandial serum 
paraoxonase activity in patients with diabetes.Eur. J. Clin. Nutr. Vol.55, pp.951–958. 
www.intechopen.com
 
Role of the Adipocyte in Development of Type 2 Diabetes 
 
194 
Welch, G.N. Loscalzo, J. (1998). Homocysteine and atherothrombosis. N. Engl. J. Med. 
Vol.338, pp.1042–1050.  
Wollesen, F., Brattsrom, L., Refsum, H., Ueland, P.M., Berglund, L., Berne, C. (1999). Plasma 
total homocysteine and cysteine in relation to glomerular filtration rate in diabetes 
mellitus. Kidney Int. vol.55, pp.1028-35. 
Yeromenko, Y., Lavie, L., Levy, Y. (2000). Homocysteine and cardiovascular risk in patients 
with diabetes mellitus. Nutr Metab Cardiovasc Dis. Vol.11, pp.108-16. 
www.intechopen.com
Role of the Adipocyte in Development of Type 2 Diabetes
Edited by Dr. Colleen Croniger
ISBN 978-953-307-598-3
Hard cover, 372 pages
Publisher InTech
Published online 22, September, 2011
Published in print edition September, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Adipocytes are important in the body for maintaining proper energy balance by storing excess energy as
triglycerides. However, efforts of the last decade have identified several molecules that are secreted from
adipocytes, such as leptin, which are involved in signaling between tissues and organs. These adipokines are
important in overall regulation of energy metabolism and can regulate body composition as well as glucose
homeostasis. Excess lipid storage in tissues other than adipose can result in development of diabetes and
nonalcoholic fatty liver disease (NAFLD). In this book we review the role of adipocytes in development of
insulin resistance, type 2 diabetes and NAFLD. Because type 2 diabetes has been suggested to be a disease
of inflammation we included several chapters on the mechanism of inflammation modulating organ injury.
Finally, we conclude with a review on exercise and nutrient regulation for the treatment of type 2 diabetes and
its co-morbidities.
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